Navigation Links
Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Date:4/24/2009

nce the therapeutic effects of exenatide by ensuring patient compliance and providing more consistent, round-the-clock therapeutic drug levels; and to reduce side effects, including nausea, associated with high peak levels of exenatide exposure observed with injection administration. Unlike other extended delivery technologies such as polymers or albumin fusion, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required.

"We are very pleased with the rapid progress the Company has made with ITCA 650," said Alice Leung, President & CEO of Intarcia. "Our team has demonstrated the great potential for DUROS delivered therapies in advancing this important treatment candidate for type 2 diabetes patients from an idea to clinical stage development in 18 months."

ITCA 650 is the second DUROS delivery program Intarcia has moved into clinical development. In December 2008, Intarcia also completed enrollment of a phase 1b study for ITCA 638, which involves DUROS delivery of omega interferon for the treatment of chronic hepatitis C infection. "Many patients with type 2 diabetes are forced to manage dosing schedules and side effects of multiple drug therapies simultaneously to adequately control their disease," commented Ken Luskey, M.D., VP, Clinical Research at Intarcia. "We believe ITCA 650 will deliver improved glycemic control and provide a better tolerated, more convenient treatment option."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Colo. , July 6, 2015 ... encorafenib, was showcased this past weekend at the ... an oral presentation.  At the meeting, data were ... data from a 100-patient randomized Phase 2 expansion ... and cetuximab, an EGFR inhibitor, with or without ...
(Date:7/6/2015)... July 6, 2015 Akcea Therapeutics, a ... ISIS ), announced today that the U.S. Food ... to volanesorsen (ISIS-APOCIII Rx ) for the treatment ... is a rare genetic disease characterized by extremely ... a Phase 2 study published in the NEJM ...
(Date:7/4/2015)... , España, July 4, 2015 ... a la quimioterapia de primera línea para pacientes ... hígado (mCRC) extiende la supervivencia libre de progresión ... cáncer colorrectal metastásico no resecable (mCRC) que se ... mejora en la supervivencia libre de progresión (PFS) ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... SAN DIEGO, Sept. 30 Cadence Pharmaceuticals, Inc. (Nasdaq: ... developing and commercializing proprietary product candidates principally for use ... host a live webcast of its Analyst Day on ... Cadence,s senior management team, led by Ted Schroeder, ...
... Sept. 30 Fifty-nine percent ... by general practitioners, according to a research report published ... study, conducted by researchers from Thomson Reuters and the ... analyzed prescribing patterns for psychotropic drugs from August 2006 ...
Cached Medicine Technology:Cadence Pharmaceuticals to Webcast October 7th Analyst Day 2Cadence Pharmaceuticals to Webcast October 7th Analyst Day 3General Practitioners Write Most Prescriptions for Mental Health Drugs, According to Study from Thomson Reuters and SAMHSA 2
(Date:7/6/2015)... ... July 06, 2015 , ... The School of ... to support a three-year effort to reduce rates of diabetes and cardiovascular disease ... partnership with the Morehouse School of Medicine’s Prevention Research Center and the Satcher ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to his ... to dissolve fat cells and is the first of its kind to be approved ... known as a double chin. Dr. Green participated in clinical trials for Kybella and ...
(Date:7/6/2015)... News, VA (PRWEB) , ... July 06, 2015 ... ... today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® ... Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 ...
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and a generous grant ... Music & Memory Certification for hospice patients and adult day center participants. , The ... to patients but also to their families and volunteers. Music & Memory is a ...
(Date:7/5/2015)... MN (PRWEB) , ... July 06, 2015 , ... ... the ancillary benefits market, is excited to announce the next generation of PrimeStar ... and Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and ...
Breaking Medicine News(10 mins):Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... more than 25 countries will converge on Boston ... 2008 Annual,Conference & Exhibition. The annual event is ... in the healthcare product sector., The regulatory ... job responsibilities related to ensuring that healthcare,products in ...
... become a "difficult patient" before she could get her physicians ... , And once the diagnosis was made, she had to ... she could get the best treatment for scleroderma, a chronic ... major element. , Mayer, a research assistant professor of health ...
... Clinics of Georgia is proud to announce Dr. Chad Levitt, a ... RCOG,s Cumming, GA. Dr. Levitt specializes in head & neck, breast, ... ... Atlanta, GA. (PRWEB) September 10, 2008 -- Board Certified Radiation Oncologist ...
... specializing in risk assessment for diabetics, recently announced that The Hope ... provide retinal imaging risk assessment. , ... Wake Forest, ... Healthcare, a Wake Forest, NC company specializing in risk assessment for ...
... Steve Poizner Will Present Keynote Address at the 6th Annual California ... event is open to the public and brings together over 500 ... lively discussion, and networking. , ... Huntington Beach, CA ...
... BOSTON, Mass. (Sep. 10, 2008)In recent years, private ... investment opportunities. Spurred by investigative reports and anecdotal ... of care, many companies have found themselves under ... a new study, such conclusions may be premature. ...
Cached Medicine News:Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 2Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 3Health News:Survival instincts propel 'difficult patient' to insist on quality care 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 3Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 2Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 3Health News:The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients 2Health News:Council on Education in Management Announces Insurance Commissioner Steve Poizner Will Present Keynote Address at the 6th Annual California Workers' Comp Forum 2Health News:Private equity companies purchase nursing homes, but care does not suffer 2Health News:Private equity companies purchase nursing homes, but care does not suffer 3
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
The MICROsed-System is the ideal system back up support to be used as front-line instrument with small workloads....
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: